Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
The DOI matches its Crossref record; 75 of the 77 references it cites were found in a registry or an index.
Abstract
Heterozygous mutations in catalytic arginine residues of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) are common in glioma, acute myeloid leukemia, chondrosarcoma, cholangiocarcinoma, and angioimmunoblastic T-cell lymphoma. The mutant enzymes acquire a neomorphic activity that converts α-ketoglutarate (α-KG) to D-2-hydroxyglutarate (D2HG), a rare metabolite. In cells and tissues expressing mutant IDH, D2HG concentrations are highly elevated. D2HG may act as an “oncometabolite” by inhibiting a class of α-KG–dependent enzymes involved in epigenetic regulation, collagen synthesis, and cell signaling. Knock-in mouse models of IDH1 mutations have shed light on these mechanisms and will provide valuable animal models for further investigation. Significance: Mutations in IDH1 and IDH2 promote the development of a number of malignancies. These active site mutations cause a gain-of-function leading to the accumulation of the rare metabolite D2HG. Mouse models of these mutations should provide insights into the mechanisms driving tumorigenesis and facilitate evaluation of new treatments. Cancer Discov; 3(7); 730–41. ©2013 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [7]
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [7]
In the citing paper
“Insulator dysfunction may also be accompanied by promoter silencing events28,29, and by alterations to other pathways affected by 2-HG7,30.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [7]
In the citing paper
“This can occur through multiple distinct mechanisms, including recurrent gain- or loss-of function mutations in enhancer of zeste 2 (EZH2), the primary methyltransferase responsible for this histone modification 99 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [99]
In the citing paper
“EZH2 catalyses mono-, di- and tri-methylation of H3K27, which is linked to transcriptional silencing 99 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [99]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Self-citationCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature · doi:10.1038/nature10602 · Cited by 1,791
Reductive carboxylation supports growth in tumour cells with defective mitochondria
Mullen, A. R., Wheaton, W. W., Jin, E. S., Chen, P.-H., Sullivan, L. B., Cheng, T., Yang, Y., Linehan, W. M., Chandel, N. S., & DeBerardinis, R. J. (2012) · Nature · doi:10.1038/nature10642 · Cited by 1,328
Collagens, modifying enzymes and their mutations in humans, flies and worms
Myllyharju, J. (2004) · Trends in Genetics · doi:10.1016/j.tig.2003.11.004 · Cited by 1,180
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119
Analysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027
Amary, M. F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F., Pollock, R., O'Donnell, P., Grigoriadis, A., Diss, T., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2913 · Cited by 1,023
Wise, D. R., Ward, P. S., Shay, J. E. S., Cross, J. R., Gruber, J. J., Sachdeva, U. M., Platt, J. M., DeMatteo, R. G., Simon, M. C., & Thompson, C. B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117773108 · Cited by 975
Quivoron, C., Couronné, L., Della Valle, V., Lopez, C. K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.-H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.003 · Cited by 924
2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas
Choi, C., Ganji, S. K., DeBerardinis, R. J., Hatanpaa, K. J., Rakheja, D., Kovacs, Z., Yang, X.-L., Mashimo, T., Raisanen, J. M., Marin-Valencia, I., et al. (2012) · Nature Medicine · doi:10.1038/nm.2682 · Cited by 839
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804
Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092506 · Cited by 736
Self-citationBorger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0386 · Cited by 728
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wadleigh, M., Malinge, S., Yao, J., Kilpivaara, O., Bhat, R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-210039 · Cited by 727
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., et al. (2012) · Nature · doi:10.1038/nature10898 · Cited by 727
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Losman, J.-A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., Cowley, G. S., Root, D. E., Ebert, B. L., & Kaelin, W. G. (2013) · Science · doi:10.1126/science.1231677 · Cited by 703
The role of mutations in epigenetic regulators in myeloid malignancies
Shih, A. H., Abdel-Wahab, O., Patel, J. P., & Levine, R. L. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3343 · Cited by 611
Graus-Porta, D., Blaess, S., Senften, M., Littlewood-Evans, A., Damsky, C., Huang, Z., Orban, P., Klein, R., Schittny, J. C., & Müller, U. (2001) · Neuron · doi:10.1016/s0896-6273(01)00374-9 · Cited by 559
Pansuriya, T. C., van Eijk, R., d'Adamo, P., van Ruler, M. A. J. H., Kuijjer, M. L., Oosting, J., Cleton-Jansen, A.-M., van Oosterwijk, J. G., Verbeke, S. L. J., Meijer, D., et al. (2011) · Nature Genetics · doi:10.1038/ng.1004 · Cited by 559
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics
Sasaki, M., Knobbe, C. B., Munger, J. C., Lind, E. F., Brenner, D., Brüstle, A., Harris, I. S., Holmes, R., Wakeham, A., Haight, J., et al. (2012) · Nature · doi:10.1038/nature11323 · Cited by 513
Self-citationIDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma
Cairns, R. A., Iqbal, J., Lemonnier, F., Kucuk, C., de Leval, L., Jais, J.-P., Parrens, M., Martin, A., Xerri, L., Brousset, P., et al. (2012) · Blood · doi:10.1182/blood-2011-11-391748 · Cited by 509
Self-citationLemonnier, F., Couronné, L., Parrens, M., Jaïs, J.-P., Travert, M., Lamant, L., Tournillac, O., Rousset, T., Fabiani, B., Cairns, R. A., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408542 · Cited by 455
Self-citationProfiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome
Reitman, Z. J., Jin, G., Karoly, E. D., Spasojevic, I., Yang, J., Kinzler, K. W., He, Y., Bigner, D. D., Vogelstein, B., & Yan, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019393108 · Cited by 449
Monoclonal antibody specific for IDH1 R132H mutation
Capper, D., Zentgraf, H., Balss, J., Hartmann, C., & von Deimling, A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0595-z · Cited by 436
Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2
Amary, M. F., Damato, S., Halai, D., Eskandarpour, M., Berisha, F., Bonar, F., McCarthy, S., Fantin, V. R., Straley, K. S., Lobo, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.994 · Cited by 428
Wang, P., Dong, Q., Zhang, C., Kuan, P.-F., Liu, Y., Jeck, W. R., Andersen, J. B., Jiang, W., Savich, G. L., Tan, T.-X., et al. (2013) · Oncogene · doi:10.1038/onc.2012.315 · Cited by 399
Iqbal, J., Weisenburger, D. D., Greiner, T. C., Vose, J. M., McKeithan, T., Kucuk, C., Geng, H., Deffenbacher, K., Smith, L., Dybkaer, K., et al. (2010) · Blood · doi:10.1182/blood-2009-06-227579 · Cited by 392
Inhibition of 2-oxoglutarate dependent oxygenases
Rose, N. R., McDonough, M. A., King, O. N. F., Kawamura, A., & Schofield, C. J. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00203h · Cited by 390
Bleeker, F. E., Lamba, S., Leenstra, S., Troost, D., Hulsebos, T., Vandertop, W. P., Frattini, M., Molinari, F., Knowles, M., Cerrato, A., et al. (2009) · Human Mutation · doi:10.1002/humu.20937 · Cited by 363
Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers
Kang, M. R., Kim, M. S., Oh, J. E., Kim, Y. R., Song, S. Y., Seo, S. I., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2009) · International Journal of Cancer · doi:10.1002/ijc.24379 · Cited by 313
Sasaki, M., Knobbe, C. B., Itsumi, M., Elia, A. J., Harris, I. S., Chio, I. I. C., Cairns, R. A., McCracken, S., Wakeham, A., Haight, J., et al. (2012) · Genes & Development · doi:10.1101/gad.198200.112 · Cited by 296
Self-citationAll the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
Labussière, M., Idbaih, A., Wang, X.-W., Marie, Y., Boisselier, B., Falet, C., Paris, S., Laffaire, J., Carpentier, C., Crinière, E., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e1cf3a · Cited by 260
Hewitson, K. S., Liénard, B. M. R., McDonough, M. A., Clifton, I. J., Butler, D., Soares, A. S., Oldham, N. J., McNeill, L. A., & Schofield, C. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608337200 · Cited by 235
Lee, B. H., Tothova, Z., Levine, R. L., Anderson, K., Buza-Vidas, N., Cullen, D. E., McDowell, E. P., Adelsperger, J., Fröhling, S., Huntly, B. J. P., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.031 · Cited by 230
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo
Popovici-Muller, J., Saunders, J. O., Salituro, F. G., Travins, J. M., Yan, S., Zhao, F., Gross, S., Dang, L., Yen, K. E., Yang, H., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300225h · Cited by 200
An in vivo patient-derived model of endogenous IDH1-mutant glioma
Luchman, H. A., Stechishin, O. D., Dang, N. H., Blough, M. D., Chesnelong, C., Kelly, J. J., Nguyen, S. A., Chan, J. A., Weljie, A. M., Cairncross, J. G., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nor207 · Cited by 198
IDH2 Mutations in Patients with d -2-Hydroxyglutaric Aciduria
Kranendijk, M., Struys, E. A., van Schaftingen, E., Gibson, K. M., Kanhai, W. A., van der Knaap, M. S., Amiel, J., Buist, N. R., Das, A. M., de Klerk, J. B., et al. (2010) · Science · doi:10.1126/science.1192632 · Cited by 195
Magnetic Resonance of 2-Hydroxyglutarate in IDH1 -Mutated Low-Grade Gliomas
Elkhaled, A., Jalbert, L. E., Phillips, J. J., Yoshihara, H. A. I., Parvataneni, R., Srinivasan, R., Bourne, G., Berger, M. S., Chang, S. M., Cha, S., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002796 · Cited by 180
A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation
Duncan, C. G., Barwick, B. G., Jin, G., Rago, C., Kapoor-Vazirani, P., Powell, D. R., Chi, J.-T., Bigner, D. D., Vertino, P. M., & Yan, H. (2012) · Genome Research · doi:10.1101/gr.132738.111 · Cited by 176
IDH mutations in acute myeloid leukemia
Rakheja, D., Konoplev, S. N., Medeiros, L. J., & Chen, W. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.05.003 · Cited by 152
Molecular pathogenesis of IDH mutations in gliomas
Ichimura, K. (2012) · Brain Tumor Pathology · doi:10.1007/s10014-012-0090-4 · Cited by 150
l‐2‐Hydroxyglutaric aciduria, a defect of metabolite repair
Rzem, R., Vincent, M. ‐., Van Schaftingen, E., & Veiga‐da‐Cunha, M. (2007) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-007-0487-0 · Cited by 149
Patnaik, M. M., Hanson, C. A., Hodnefield, J. M., Lasho, T. L., Finke, C. M., Knudson, R. A., Ketterling, R. P., Pardanani, A. D., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.298 · Cited by 147
Müller, T., Gessi, M., Waha, A., Isselstein, L., Luxen, D., Freihoff, D., Freihoff, J., Becker, A. J., Simon, M., Hammes, J., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.04.017 · Cited by 143
Capper, D., Reuß, D., Schittenhelm, J., Hartmann, C. J., Bremer, J., Sahm, F., Harter, P. N., Jeibmann, A., & von Deimling, A. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0770-2 · Cited by 142
HIF-independent role of prolyl hydroxylases in the cellular response to amino acids
Durán, R. V., MacKenzie, E. D., Boulahbel, H., Frezza, C., Heiserich, L., Tardito, S., Bussolati, O., Rocha, S., Hall, M. N., & Gottlieb, E. (2013) · Oncogene · doi:10.1038/onc.2012.465 · Cited by 139
Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Jin, G., Reitman, Z. J., Duncan, C. G., Spasojevic, I., Gooden, D. M., Rasheed, B. A., Yang, R., Lopez, G. Y., He, Y., McLendon, R. E., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2852 · Cited by 125
Fathi, A. T., Sadrzadeh, H., Borger, D. R., Ballen, K. K., Amrein, P. C., Attar, E. C., Foster, J., Burke, M., Lopez, H. U., Matulis, C. R., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438267 · Cited by 123
L-2-hydroxyglutaric aciduria and brain malignant tumors: A predisposing condition?
Moroni, I., Bugiani, M., D’Incerti, L., Maccagnano, C., Rimoldi, M., Bissola, L., Pollo, B., Finocchiaro, G., & Uziel, G. (2004) · Neurology · doi:10.1212/01.wnl.0000125335.21381.87 · Cited by 118
D‐2‐hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats
Latini, A., Scussiato, K., Rosa, R. B., Llesuy, S., Belló‐Klein, A., Dutra‐Filho, C. S., & Wajner, M. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02639.x · Cited by 112
Fathi, A. T., & Abdel-Wahab, O. (2012) · Advances in Hematology · doi:10.1155/2012/469592 · Cited by 92
D‐2‐Hydroxyglutaric aciduria: Unravelling the biochemical pathway and the genetic defect
Struys, E. A. (2006) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-006-0317-9 · Cited by 89
TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations: Figure 1
Kim, Y.-H., Pierscianek, D., Mittelbronn, M., Vital, A., Mariani, L., Hasselblatt, M., & Ohgaki, H. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200133 · Cited by 74
IDH mutation status in prostate cancer
Ghiam, A. F., Cairns, R. A., Thoms, J., Pra, A. D., Ahmed, O., Meng, A. X., Mak, T. W., & Bristow, R. G. (2011) · Oncogene · doi:10.1038/onc.2011.546 · Cited by 71
Self-citationKim, W., & Liau, L. M. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.04.009 · Cited by 69
van Oosterwijk, J. G., de Jong, D., van Ruler, M. A. J. H., Hogendoorn, P. C. W., Dijkstra, P. S., van Rijswijk, C. S., Machado, I., Llombart‐Bosch, A., Szuhai, K., & Bovée, J. V. M. G. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-375 · Cited by 50
Pathobiology and Molecular Profiling of Peripheral T-Cell Lymphomas
de Leval, L., & Gaulard, P. (2008) · Hematology · doi:10.1182/asheducation-2008.1.272 · Cited by 40
Mutant IDH1 is required for IDH1 mutated tumor cell growth
Jin, G., Pirozzi, C. J., Chen, L. H., Lopez, G. Y., Duncan, C. G., Feng, J., Spasojevic, I., Bigner, D. D., He, Y., & Yan, H. (2012) · Oncotarget · doi:10.18632/oncotarget.577 · Cited by 35
Enzyme redesign guided by cancer-derived IDH1 mutations
Reitman, Z. J., Choi, B. D., Spasojević, I., Bigner, D. D., Sampson, J. H., & Yan, H. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1065 · Cited by 25
IDHmutations: new genetic signatures in cholangiocarcinoma and therapeutic implications
Borger, D. R., & Zhu, A. X. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.32 · Cited by 23
Angioimmunoblastic T-cell lymphoma mice model
Sato, F., Ishida, T., Ito, A., Mori, F., Masaki, A., Takino, H., Narita, T., Ri, M., Kusumoto, S., Suzuki, S., et al. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.09.009 · Cited by 20
Mauzo, S. H., Lee, M., Petros, J. A., HUNTER, S. B., Chang, C.-M., Shu, H. G., Bellail, A. C., Hao, C., & Cohen, C. (2013) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e3182649d1c · Cited by 17
Cited by
Epigenetic plasticity and the hallmarks of cancer
Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340
Insulator dysfunction and oncogene activation in IDH mutant gliomas
Flavahan, W. A., Drier, Y., Liau, B. B., Gillespie, S. M., Venteicher, A. S., Stemmer-Rachamimov, A. O., Suvà, M. L., & Bernstein, B. E. (2016) · Nature · doi:10.1038/nature16490 · Cited by 1,288
Oxidative stress and metabolic disorders: Pathogenesis and therapeutic strategies
Rani, V., Deep, G., Singh, R. K., Palle, K., & Yadav, U. C. S. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.02.002 · Cited by 1,139
Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
Easwaran, H., Tsai, H.-C., & Baylin, S. B. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.015 · Cited by 915
Metabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2022) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 770
“, 2010) constitute the majority of mutational events and lead to the occurrence of GBM, AML, chondrosarcoma, cholangiocarcinoma, and angioimmunoblastic T-cell lymphoma (Cairns and Mak, 2013; Lu et al., 2013).”
Background
Metadata
- Authors
- Cairns, R. A., & Mak, T. W.
- Affiliations
- University Health Network (CA)
- Venue
- Cancer Discovery
- Published
- 2013-07-01
- Volume
- 3
- Issue
- 7
- Pages
- 730-741
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2111163869
- Cited by
- 452
- References
- 77
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 26 · 2023: 26 · 2022: 31 · 2021: 33 · 2020: 45 · 2019: 33 · 2018: 43 · 2017: 46 · 2016: 50 · 2015: 44 · 2014: 37 · 2013: 4
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- IDH mutation, IDH1, IDH2, 2-hydroxyglutarate, oncometabolites, alpha-ketoglutarate, gain-of-function mutations, epigenetic regulation, collagen synthesis, knock-in mice, glioma, acute myeloid leukemia, cholangiocarcinoma, angioimmunoblastic T-cell lymphoma, chondrosarcoma, carcinogenesis
- MeSH terms
- Animals, Arginine, Glutarates, Humans, Isocitrate Dehydrogenase, Mutation, Neoplasms, Gene Expression Regulation, Neoplastic, Epigenesis, Genetic, Mice, Gene Knock-In Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.